Large gap with delayed quotes
|
Last quote
07/01/2025
-
16:20:15
|
Bid
07/01/2025 -
16:20:15
|
Bid Volume |
Ask
07/01/2025 -
16:20:15
|
Ask Volume |
|---|---|---|---|---|
|
17.53
+0.22
(
+1.27% )
|
17.50
|
100 |
17.53
|
500 |
Analysis date: 27.06.2025
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 17.06.2025.
Interest
Weak
Weak
Two stars since 27.06.2025.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 30.05.2025 at a price of 16.93.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Negative
Negative
The forty day technical trend is negative since 17.06.2025.
4wk Rel Perf
-1.05%
-1.05%
The four-week dividend-adjusted underperformance versus SP500 is 1.05%.
Sensibility
High
High
The stock has been on the high-sensitivity level since 11.10.2024.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 4.81%.
Mkt Cap in $bn
2.19
2.19
With a market capitalization between $2 & $8bn, APELLIS PHARMS. is considered a mid-cap stock.
G/PE Ratio
4.67
4.67
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
12.85
12.85
The estimated PE is for the year 2028.
LT Growth
60.02%
60.02%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
18
18
Over the last seven weeks, an average of 18 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
88
88
For 1% of index variation, the stock varies on average by 0.88%.
Correlation
0.34
0.34
Stock movements are strongly independent of index variations.
Value at Risk
6.17
6.17
The value at risk is estimated at USD 6.17. The risk is therefore 35.37%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
22.04.2022
22.04.2022